

IPTR LEVEL 2: THESE MEDICINES REQUIRE THE COMPLETION OF FORM IPTR 2 AND APPROVAL BY THE RELEVANT CLINICAL DIRECTOR PRIOR TO SUPPLY. APPLICABLE TO ALL SPECIALTIES *OTHER THAN* SPECIALIST ONCOLOGY.

Agomelatine¹

Ceftolozane with tazobactam (Zerbaxa®)¹

Prucalopride¹

Tapentadol immediate release¹

Tramacet®¹

Ranolazine¹

IPTR LEVEL 3: THESE MEDICINES REQUIRE THE COMPLETION OF FORM IPTR 3 AND APPROVAL BY AN IPTR PANEL PRIOR TO PRESCRIBING. APPLICABLE TO ALL SPECIALTIES *OTHER THAN* SPECIALIST ONCOLOGY.

Abatacept (Orencia®)

- Rheumatoid arthritis not previously treated with methotrexate¹

Adalimumab (Humira®)

- Moderately active Crohn's disease¹
- First-line for moderate to severe chronic plaque psoriasis¹
- Uveitis¹

Alglucosidase alfa 50mg infusion (Myozyme®)¹

Amifampridine (Firdapse®)¹

Anakinra (Kineret®)¹

Bosentan (Tracleer®)

- for treatment of digital ulcers in patients with systemic sclerosis¹
- for pulmonary arterial hypertension (class II)¹

Botulinum toxin type A (Botox®)

- for lower limb spasticity associated with stroke¹

Canakinumab (Ilaris®)

- Cryopyrin-Associated Periodic Syndromes (CAPS)¹
- Gouty arthritis¹
- Systemic juvenile arthritis¹
- Still's disease¹
- Autoinflammatory periodic fever syndromes¹

Cannabinoid Extract Spray (Sativex®)¹

Caspafungin acetate (Caspofungin®)

- for invasive aspergillosis¹

Certolizumab (Cimzia®)¹

- rheumatoid arthritis not previously treated with methotrexate or DMARDs

Cinacalcet (Mimpara®)

- for hypercalcaemia in parathyroid carcinoma¹
- for reduction of hypercalcaemia in patients with primary hyperparathyroidism¹

Cobicistat (Tybost®)¹

Collagenase clostridium histolyticum (Xiapex®)

- Peyronie's disease¹

Daptomycin (Cubicin®)¹

- for complicated skin and soft-tissue infections in paediatric patients

Deferasirox (Exjade®)

- Treatment of chronic iron overload requiring chelation therapy in non-transfusion-dependent thalassaemia syndromes¹

Eltrombopag olamine (Revolade®)

- acquired severe aplastic anaemia (SAA)¹

Emtricitabine with tenofovir (Truvada®)

- HIV-1 in 12 to <18 year olds with NRTI resistance intolerant of first line agents¹

Entecavir (Baraclude®)

- for chronic hepatitis B virus infection in adults with decompensated liver disease¹

Etelcalcetide (Parsabiv®)¹

Everolimus (Votubia®)

- for renal angiomyolipoma associated with tuberous sclerosis complex (TSC)¹

Everolimus (Cetican®)

- for prophylaxis of organ rejection in cardiac or hepatic transplant¹

Fampridine (Fampyra®)¹

Fosamprenavir (Telzir®)

- for HIV infection in children > 6 years and adolescents¹

Golimumab (Simponi®)¹

- 2nd line treatment polyarticular juvenile idiopathic arthritis in children ≥40kg

Human alpha1-proteinase inhibitor (Respreeza®)¹

Hydrocortisone MR tablets (Plenadren®)¹

Idursulfase (Elaprase®)¹

Infliximab (Remicade®)

- moderately active Crohn's disease¹

Interferon beta-1a (Rebif®)

- for a single demyelinating event¹

Interferon beta-1b (Betaferon®/Extavia®)

- for a single demyelinating event¹

Ivacaftor tablets (Kalydeco®)¹

- for all mutations other than G551D mutation and R117H mutation

Ketoconazole (Ketoconazole HRA®)¹

Key to reason why IPTR required:

1. Not recommended for use in NHS Scotland by the Scottish Medicines Consortium or following advice from NHS Health Improvement Scotland
2. Awaiting evaluation by the Scottish Medicines Consortium
3. Note: Other indications may not be subject to the same mechanism of access

- endogenous Cushing's syndrome in adults and adolescents above the age of 12 years
- Laronidase (Aldurazyme[®])¹
- Lumacaftor with ivacaftor (Orkambi[®])¹
- Maraviroc (Celsentri[®])¹
- Micafungin (Mycamin[®])
 - for oesophageal candidiasis¹
 - for prophylaxis of Candida infection in stem cell transplant patients¹
- Miglustat (Zavesca[®])
 - for Niemann-Pick Type C disease¹
- Natalizumab (Tysabri[®])¹
 - 2nd line treatment for highly active relapsing remitting multiple sclerosis
- Olanzapine long-acting injection (ZypAdhera[®])¹
- Pasireotide (Signifor[®])¹
 - treatment of Cushing's disease in adults for whom surgery is not an option or for whom surgery has failed
- Pegaptanib (Macugen[®])¹
- Pegvisomant (Somavert[®])¹
- Perampanel (Fycompa[®])¹
 - primary generalised tonic-clonic seizures in idiopathic generalised epilepsy
- Pitolisant (Wakix[®])¹
- Raltegravir (Isentress[®])
 - for use out with the SMC restrictions¹ which states: restricted to patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or

- when these options are compromised due to drug-drug interactions.
- Rabbit anti-human thymocyte immunoglobulin (Thymoglobuline[®])¹
 - Ruxolitinib phosphate (Jakavi[®])¹
 - polycythaemia vera
 - Sapropterin (Kuvan[®])¹
 - Selexipag (Uptravi[®])¹
 - Sodium Oxybate (Xyrem[®])¹
 - Stiripentol (Diacomit[®])¹
 - Sufentanil (Zalviso[®])¹
 - Tafamidis meglumine (Vyndaqel[®])¹
 - Teduglutide (Revestive[®])¹
 - Telavancin hydrochloride (Vibativ[®])¹
 - Tenofovir alafenamide (Vemlidy[®])¹
 - Teriparatide (Forsteo[®])
 - for treatment of osteoporosis in men¹
 - For osteoporosis associated with sustained glucocorticoid therapy¹
 - Tocilizumab (RoActemra[®])¹
 - severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate
 - Tocofersolan (Vedrop[®])¹
 - Tolvaptan (Samsca[®])¹
 - Vernakalant (Brinavess[®])¹
 - Voriconazole (Vfend[®])¹
 - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients
 - Ziconotide (Prialt[®])¹

PACS: THESE MEDICINES REQUIRE THE COMPLETION OF PACS FORM AND THE APPROVAL OF A PACS PANEL PRIOR TO PRESCRIBING . APPLICABLE TO ALL SPECIALTIES *OTHER THAN* SPECIALIST ONCOLOGY.

- Ataluren (Translarna[®])
 - For the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation¹
- Eculizumab (Soliris[®])
 - for paroxysmal nocturnal haemoglobinuria¹
 - for atypical haemolytic uremic syndrome (aHUS)¹
- Elosulfase alfa (Vimizim[®])¹
- Ivacaftor (Kalydeco[®])¹
 - tablets for R117H mutation in adults¹
 - granules all mutations in children age 2 and older weighing less than 25kg¹

Key to reason why IPTR required:

1. Not recommended for use in NHS Scotland by the Scottish Medicines Consortium or following advice from NHS Health Improvement Scotland
2. Awaiting evaluation by the Scottish Medicines Consortium
3. Note: Other indications may not be subject to the same mechanism of access